163 related articles for article (PubMed ID: 10119215)
1. Selection of licensing candidates in the pharmaceutical industry: an application of the analytic hierarchy process.
Ross ME; Nydick RL
J Health Care Mark; 1992 Jun; 12(2):60-5. PubMed ID: 10119215
[TBL] [Abstract][Full Text] [Related]
2. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
3. Pharmaceutical new product development: the increasing role of in-licensing.
Edwards NV
Anesthesiol Clin; 2008 Dec; 26(4):627-36, v. PubMed ID: 19041620
[TBL] [Abstract][Full Text] [Related]
4. An unbalanced portfolio.
Federsel HJ
Drug News Perspect; 2009 Jun; 22(5):287-92. PubMed ID: 19609466
[TBL] [Abstract][Full Text] [Related]
5. Merck's recall of rofecoxib--a strategic perspective.
Oberholzer-Gee F; Inamdar SN
N Engl J Med; 2004 Nov; 351(21):2147-9. PubMed ID: 15548771
[No Abstract] [Full Text] [Related]
6. New estimates of drug development costs.
Frank RG
J Health Econ; 2003 Mar; 22(2):325-30. PubMed ID: 12606149
[No Abstract] [Full Text] [Related]
7. The price of innovation: new estimates of drug development costs.
DiMasi JA; Hansen RW; Grabowski HG
J Health Econ; 2003 Mar; 22(2):151-85. PubMed ID: 12606142
[TBL] [Abstract][Full Text] [Related]
8. Model-based drug development survey finds pharmacometrics impacting decision making in the pharmaceutical industry.
Stone JA; Banfield C; Pfister M; Tannenbaum S; Allerheiligen S; Wetherington JD; Krishna R; Grasela DM
J Clin Pharmacol; 2010 Sep; 50(9 Suppl):20S-30S. PubMed ID: 20881214
[TBL] [Abstract][Full Text] [Related]
9. Do ads really drive pharmaceutical sales? The true effects of DTC advertising remain a mystery.
Findlay S
Mark Health Serv; 2002; 22(1):20-5. PubMed ID: 11881540
[TBL] [Abstract][Full Text] [Related]
10. Why are pharmaceutical companies gradually abandoning vaccines?
Offit PA
Health Aff (Millwood); 2005; 24(3):622-30. PubMed ID: 15886152
[TBL] [Abstract][Full Text] [Related]
11. Payers growing influence on R&D decision making.
Hughes B
Nat Rev Drug Discov; 2008 Nov; 7(11):876-8. PubMed ID: 18974741
[No Abstract] [Full Text] [Related]
12. A better prescription for drug-development financing.
Kessel M; Frank F
Nat Biotechnol; 2007 Aug; 25(8):859-66. PubMed ID: 17687358
[No Abstract] [Full Text] [Related]
13. Factors affecting U.S. manufacturers' decisions to produce vaccines.
Coleman MS; Sangrujee N; Zhou F; Chu S
Health Aff (Millwood); 2005; 24(3):635-42. PubMed ID: 15886154
[TBL] [Abstract][Full Text] [Related]
14. What's next in translational medicine?
Littman BH; Di Mario L; Plebani M; Marincola FM
Clin Sci (Lond); 2007 Feb; 112(4):217-27. PubMed ID: 17223795
[TBL] [Abstract][Full Text] [Related]
15. Medical decision support using the Analytic Hierarchy Process.
Sloane EB; Liberatore MJ; Nydick RL
J Healthc Inf Manag; 2002; 16(4):38-43. PubMed ID: 12365298
[TBL] [Abstract][Full Text] [Related]
16. Productivity counts--but the definition is key.
Mervis J
Science; 2005 Jul; 309(5735):726. PubMed ID: 16051784
[No Abstract] [Full Text] [Related]
17. A decision analytic approach to a futility analysis of a phase II pharmaceutical study.
Pallay A
J Biopharm Stat; 2001 Nov; 11(4):209-25. PubMed ID: 12018776
[TBL] [Abstract][Full Text] [Related]
18. Opinion: development of new drugs is still a risky business.
Franks B
N J Med; 2002; 99(1-2):60, 59. PubMed ID: 15326736
[No Abstract] [Full Text] [Related]
19. How should we support pharmaceutical innovation?
Grootendorst P
Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):313-20. PubMed ID: 19670991
[TBL] [Abstract][Full Text] [Related]
20. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
